US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

11.39

+0.64005.95%

Post-market: 11.390.00000.00%19:51 EDT

Volume:532.80K

Turnover:6.19M

Market Cap:614.88M

PE:-1.91

High:12.11

Open:10.87

Low:10.75

Close:10.75

52wk High:17.40

52wk Low:7.90

Shares:53.98M

Float Shares:17.65M

Volume Ratio:0.71

T/O Rate:3.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.9500

EPS(LYR):-115.2900

ROE:-125.02%

ROA:-36.19%

PB:1.32

PE(LYR):-0.10

Loading ...

Overview Company News Filings

Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley

Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush

Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress

Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate

Benzinga Earnings

Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial

Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned

THOMSON REUTERS

Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma

THOMSON REUTERS

Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board

THOMSON REUTERS

Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board

Eikon Therapeutics Announces Recent Board Director Resignations

Eikon Therapeutics Directors Leon Chen, Joshua Wolfe Resign from Board

Eikon Therapeutics Doses First Patient in TeLuRide-008 Phase 2/3 NSCLC Trial of Eik1001 Combo

Eikon Therapeutics Announces First Patient Dosed in Teluride-008, a Registrational Phase 2/3 Trial of Eik1001 in Non-Small Cell Lung Cancer

THOMSON REUTERS

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Eikon Therapeutics Flags Availability of ESMO 2026 Abstracts Press Release

EIKN’s TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/EIKN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":11.39,"timestamp":1787342400000,"preClose":10.75,"halted":0,"volume":532797,"hourTrading":{"tag":"盘后","latestPrice":11.39,"preClose":11.39,"latestTime":"19:51 EDT","volume":1595,"amount":18156.859,"timestamp":1787356271240,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.059534883720930284,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"Market Closed","change":0.64,"latestTime":"08-21 16:00:00 EDT","open":10.87,"high":12.11,"low":10.75,"amount":6192018.616434,"amplitude":0.126512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.95,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":10.75,"preHourTrading":{"tag":"盘前","latestPrice":10.84,"preClose":10.75,"latestTime":"09:28 EDT","volume":4639,"amount":50889.704746999996,"timestamp":1787318880048,"change":0.09,"changeRate":0.008372,"amplitude":0.012093},"postHourTrading":{"tag":"盘后","latestPrice":11.39,"preClose":11.39,"latestTime":"19:51 EDT","volume":1595,"amount":18156.859,"timestamp":1787356271240,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7071557181929533},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.7071557181929533,"shares":53984300,"dividePrice":0,"high":12.11,"amplitude":0.126512,"preClose":10.75,"low":10.75,"week52Low":7.9,"pbRate":"1.32","week52High":17.4,"institutionHeld":0,"latestPrice":11.39,"eps":-5.95,"divideRate":0,"volume":532797,"delay":0,"ttmEps":-5.95,"open":10.87,"prevYearClose":18,"prevWeekClose":11.05,"prevMonthClose":9.21,"prevQuarterClose":13.05,"fiveDayClose":11.05,"twentyDayClose":8.9,"sixtyDayClose":10.37},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-08-21","current":-1.914286,"percent":0.422222,"low":-3.139466,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"high":-1.335246,"avg":-1.859189,"sd":0.392485,"marketCap":582274072},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072}],"updateTime":1787491459599},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660449477","title":"Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660449477?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084118,"startTime":"0","endTime":"0","summary":"Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncologyEikon Therapeutics will join a Cantor Fitzgerald-hosted KOL event on Aug. 20, 2026 at 9:00 a.m. ET.Chairman and C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLQxCq8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","NDAQ","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","EIKN","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4588","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00BQXX3D17.EUR","SG9999014039.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660929014","title":"Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2660929014","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660929014?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084100,"startTime":"0","endTime":"0","summary":"Event and Webcast to be held August 20th, 2026, 9:00 AM ETMILLBRAE, Calif., Aug.  18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3347241/0/en/eikon-therapeutics-to-participate-in-kol-event-on-therapeutic-use-of-parp-inhibitors-in-oncology-hosted-by-cantor-fitzgerald.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL","EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480036","title":"Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480036?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:58","pubTimestamp":1786971506,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Eikon Therapeutics, Inc., with a price target of $32.00. Laa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144099","title":"Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144099?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:29","pubTimestamp":1786714140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659433021","title":"Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659433021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659433021?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:35","pubTimestamp":1786703738,"startTime":"0","endTime":"0","summary":"An update from Eikon Therapeutics, Inc. ( ($EIKN) ) is now available. On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q3-2026-oncology-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q3-2026-oncology-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","PRGS","LU2065732104.USD","BK4139","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167560","title":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167560","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167560?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:21","pubTimestamp":1786652519,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/EIKN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659628611","title":"Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659628611","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659628611?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651485,"startTime":"0","endTime":"0","summary":"Eikon net loss narrows 16% to $88.4 million in Q2 FY26; R&D expenses rise 9% to $75.5 millionEikon reported Q2 2026 net loss attributable to common stockholders narrowed to USD 88.4 million from USD 1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3wk4Rj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","LU2210149790.SGD","EIKN","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","BCDF","IE00BN0W2V16.EUR","BK4139","IE00B64PRP62.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516286","title":"Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516286?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344893/0/en/eikon-therapeutics-reports-second-quarter-2026-financial-results-and-provides-clinical-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","L","BK4588","BK4585","BK4107","DMC","EIKN","IND","BK4189","LU0053666078.USD","LU2487616109.SGD","BK4139","BK4135","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658846997","title":"Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658846997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658846997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447894,"startTime":"0","endTime":"0","summary":"Eikon selects 0.6 mg/m2 dose for EIK1001 in TeLuRide-006 advanced melanoma trialEikon Therapeutics selected a 0.60 mg/m2 dose for EIK1001 in the ongoing TeLuRide-006 adaptive Phase 2/3 trial in advanc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2gfygh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","EIKN","SG9999014039.USD","BCDF","BK4139","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992063","title":"Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992063?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAB5KLWN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992060","title":"Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992060?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAB5KLWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658336339","title":"Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2658336339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658336339?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUAQBMQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933604","title":"Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933604?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361400,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\"Eikon\"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300172","title":"Eikon Therapeutics Announces Recent Board Director Resignations","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300172?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:32","pubTimestamp":1785796348,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics, Inc. ( ($EIKN) ) has provided an announcement. On July 31, 2026, Eikon Therapeutics, Inc., a biotechnology company focused on d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-announces-recent-board-director-resignations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-announces-recent-board-director-resignations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","DARP","IEIH","EIKN","SYNB","BK4585","RSPH","BK4139","FHLC","XT","BK4588","LNGR","IBB","AGNG","FWD","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302677","title":"Eikon Therapeutics Directors Leon Chen, Joshua Wolfe Resign from Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302677","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302677?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:51","pubTimestamp":1785790274,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics directors Leon Chen, Joshua Wolfe resign from boardEikon Therapeutics reported board resignations by Leon Chen and Joshua Wolfe, effective July 31, 2026.Both departures were not tie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL1YqtH7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654701268","title":"Eikon Therapeutics Doses First Patient in TeLuRide-008 Phase 2/3 NSCLC Trial of Eik1001 Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2654701268","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654701268?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:31","pubTimestamp":1785151900,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics doses first patient in TeLuRide-008 Phase 2/3 NSCLC trial of EIK1001 comboEikon Therapeutics dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8slyDj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD","EIKN","SG9999014013.SGD","LU2210149790.SGD","BK4585","BK4139","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","BCDF","IE00BN0W2W23.USD","SG9999014039.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012511","title":"Eikon Therapeutics Announces First Patient Dosed in Teluride-008, a Registrational Phase 2/3 Trial of Eik1001 in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012511?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:30","pubTimestamp":1785151800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA1SLY2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012763","title":"Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012763","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012763?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:30","pubTimestamp":1785151800,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., July  27, 2026  (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333400/0/en/Eikon-Therapeutics-Announces-First-Patient-Dosed-in-TeLuRide-008-a-Registrational-Phase-2-3-Trial-of-EIK1001-in-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4588","BK4139","BK4107","LU0053666078.USD","LU2487616109.SGD","L","LU0210528500.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652831213","title":"Eikon Therapeutics Flags Availability of ESMO 2026 Abstracts Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2652831213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652831213?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:01","pubTimestamp":1784548890,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics flags availability of ESMO 2026 abstracts press releaseEikon posted a press release on seven abstracts accepted for presentation at the 2026 ESMO Congress in Madrid.Updates span EIK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLb5QGSn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","EIKN","BCDF","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651607467","title":"EIKN’s TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2651607467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651607467?lang=en_us&edition=fundamental","pubTime":"2026-07-16 00:31","pubTimestamp":1784133088,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics, Inc. ($EIKN) announced an update on their ongoing clinical study. The TeLuRide-008 study from Eikon Therapeutics, Inc. tests EI...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikns-teluride-008-trial-a-new-lung-cancer-combo-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikns-teluride-008-trial-a-new-lung-cancer-combo-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","EIKN","BK4139","BK4211"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}